Leukemia Clinical Trial
— RituximabOfficial title:
A Trial of Rituximab Combined With Prednisone/Ifosfamide/Etoposide for Relapsed Acute Lymphoblastic Leukemia (ALL)
Verified date | November 2014 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
This is a pilot study of a drug called rituximab used together with other drugs—prednisone,
etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of
standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was
approved by the Food and Drug Administration in 1997. However, the use of rituximab with
prednisone, etoposide, and ifosfamide in pediatric patients with relapsed or refractory ALL
is considered experimental.
This study is for patients who have ALL in second or greater relapse, or in first relapse
and not responding to treatment.
The goals of this study are:
- To see if using rituximab with prednisone, etoposide, and ifosfamide is beneficial to
leukemia treatment
- To find out what side effects this combination of drugs can cause
A total of 15 participants (30 years old or younger) will be enrolled, over a period of 2
years.
Status | Terminated |
Enrollment | 1 |
Est. completion date | October 2012 |
Est. primary completion date | October 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 1 Year to 30 Years |
Eligibility |
Inclusion Criteria: 1. Age: Patients must be 1-30 years of age at initial diagnosis. 2. Diagnosis: Patients must have histologically-confirmed relapsed/refractory Acute Lymphoblastic Leukemia (ALL). 3. Disease Status:Patients must be in - second or greater bone marrow relapse (= 25% blasts by morphology), or - refractory to reinduction therapy with one or more attempts at remission reinduction (end of reinduction blasts = 5% by morphology and/or end of reinduction MRD = 1% by flow cytometry). - Patients with combined bone marrow and extramedullary relapse are eligible (CNS 3 patients excluded). 4. Performance Status: Patients must have a performance status of =50 from the Lansky Scale if <10 years or = 50 or from the Karnofsky Scale if = 10 years. Patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score. 5. Prior Therapy: Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet time restrictions from end of prior therapy as stated below: - Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks in the case of nitrosurea containing therapy). Patients who relapse while receiving ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study. Cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of therapy. - XRT: must be = 4 weeks since the completion of radiation therapy. - Study specific limitations: must be = 7 days since the completion of corticosteroid therapy. - Growth factor(s): Must not have received any hematopoietic growth factors (GCSF, Neulasta, or GMCSF) within 7 days of study entry. - Stem Cell Transplant: Patients must be at least two months from stem cell transplant, must be off immunosuppressives, and must have no evidence of active graft versus host disease. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair. 6. Institutional review board approval. 7. Individual informed consent per local guidelines and federal and state regulations. 8. Organ Function: All patients must have adequate organ function defined as: - Renal Function: Patients must have a calculated creatinine clearance or radioisotope GFR = 70mL/min/1.73m2 or a normal serum creatinine based on age/gender. - Liver Function: Total bilirubin = 1.5 x institutional upper limit of normal (ULN) for age, AND SGPT (ALT) = 5 x institutional ULN for age - Cardiac Function: Ejection fraction > 50% on echocardiogram or MUGA Scan, OR Shortening fraction = 27% on echocardiogram or MUGA Scan - Reproductive Function: Due to potential teratogenic effects of the drugs, all post-menarchal female patients must have a negative serum beta HCG prior to study enrollment. In addition, all patients of childbearing or child-fathering potential must agree to a medically acceptable form of contraception, including abstinence, while on study. Exclusion Criteria: 1. Patients with an active and uncontrolled infection, defined as need for pressors, and/or positive cultures for 24 hours. 2. Patients recovering from allogeneic bone marrow transplantation who are still on immunosupressants. 3. Pregnant or lactating females. Women of childbearing age will agree to use contraception during the protocol. 4. Patients currently receiving other investigational agents, medications, or supplements with a known anti-leukemic effect. 5. Patients who, in the opinion of the investigator, will not be able to comply with safety monitoring requirements of the study. 6. Patients with reactivation of hepatitis B prior to starting therapy. 7. Patients who are HIV positive. 8. Patients must not have CNS 3 involvement. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Children's Healthcare of Atlanta | Atlanta | Georgia |
United States | Emory University | Atlanta | Georgia |
United States | The children's Mercy Hospital | Kansas City | Missouri |
Lead Sponsor | Collaborator |
---|---|
Emory University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 4 Month Event Free Survival (EFS) | To estimate the 4 month EFS after therapy with rituximab and cytotoxic chemotherapy (prednisone/etoposide/ifosfamide) in patients with second relapse/refractory ALL. | one year after enrollment | No |
Primary | Toxicities of Rituximab | To describe the toxicities of rituximab in addition to prednisone, etoposide, and ifosfamide. | two months after treatment | Yes |
Primary | Remission Induction Rate | To estimate the remission induction rate of the addition of rituximab to cytotoxic chemotherapy (prednisone/etoposide/ifosfamide) in patients with second relapse/refractory ALL. | one month | No |
Secondary | Minimal Residual Disease | To perform serial minimal residual disease (MRD) measurements to provide an objective determination of the effectiveness of this therapy. | one month after treatment | No |
Secondary | Prednisone Effect | To correlate the effect of prednisone on CD20 expression using serial measurements of CD20 expression in leukemic blasts. | one month after treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |